Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.22 Analyst target: $4.60 Upside: 277.05%
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
See the full interactive analysis & chart →Informational only — not investment advice.